WNS Announces Collaboration with Snowflake to Accelerate AI and Data Modernization
WNS (Holdings) Limited (NYSE: WNS), a digital-led business transformation and services company, today announced a strategic collaboration with Snowflake, the AI Data Cloud company. This collaboration will enable organizations across industries to accelerate data modernization and leverage AI to drive improved business outcomes.
WNS' recent acquisition of Kipi.ai, a Snowflake Elite Partner, has significantly enhanced its data management, advanced analytics, and AI capabilities. Kipi.ai brings specialized expertise in data modernization and democratization with more than 600 SnowPro Core Certified Professionals, including 400 Advanced SnowPro Certified experts and three Snowflake Data Superheroes – an elite group of around 80 world-wide. Over the next two years, WNS plans to more than double its Snowflake-certified workforce to help service growing client demand.
The Snowflake AI Data Cloud enables organizations to unify data silos, perform real-time analytics, and securely share data across organizations at scale. By combining Snowflake's industry-leading data and AI platform with WNS' deep domain knowledge and AI expertise, the collaboration aims to deliver solutions that enhance operational efficiency, improve decision-making, create new revenue streams, and deliver sustainable business value for clients.
'WNS' collaboration with Snowflake strengthens our ability to help clients modernize their data infrastructure and unlock the true potential of AI. Together, we are focused on delivering practical, scalable solutions that address evolving business needs and drive measurable impact,' said Keshav R. Murugesh, Group CEO, WNS.
'WNS' commitment to building deep Snowflake expertise, supported by the acquisition of Kipi.ai, positions them well to support clients' data modernization journeys. We look forward to working together to empower every enterprise to achieve its full potential through data and AI and accelerate innovation,' said Amy Kodl, Interim Alliances & Channels Leader, Snowflake.
This strategic collaboration will serve clients across the US, UK, Europe, and Australia, combining Snowflake's cloud data capabilities with WNS' domain expertise to support data modernization initiatives and AI-driven transformation.
About WNS
WNS (Holdings) Limited (NYSE: WNS) is a digital-led business transformation and services company. WNS combines deep domain expertise with talent, technology, and AI to co-create innovative solutions for over 700 clients across various industries. WNS delivers an entire spectrum of solutions including industry-specific offerings, customer experience services, finance and accounting, human resources, procurement, and research and analytics to re-imagine the digital future of businesses. As of March 31, 2025, WNS had 64,505 professionals across 64 delivery centers worldwide including facilities in Canada, China, Costa Rica, India, Malaysia, the Philippines, Poland, Romania, South Africa, Sri Lanka, Turkey, the United Kingdom, and the United States.
For more information, visit www.wns.com or follow us on Facebook, Twitter, LinkedIn, and Instagram.
Safe Harbor Provision
Advertisement
This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 10-K and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Click here for Media Contact Details
Submit your press release
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts
Relay Therapeutics Inc. (NASDAQ:RLAY) is one of the most promising penny stocks under $5. On August 8, Raymond James lowered the firm's price target on Relay Therapeutics to $19 from $29, while keeping a Strong Buy rating on the shares. This sentiment followed Relay Therapeutics' Q2 2025 results, where OpEx was down 16% sequentially following strategic cost-cutting initiatives. Relay Therapeutics reported a net loss of $70.4 million, or $0.41 per share, in Q2 2025, which was an improvement compared to the net loss of $92.2 million, or $0.69 per share, in Q2 2024. Revenue for the quarter was $0.7 million, which was an increase from zero revenue in the same period last year. A chemist arranging containers of compounds, ready for the commercialization process. This quarter also featured the initiation of the Phase 3 ReDiscover-2 trial for RLY-2608 in Q2 2025. At the 2025 American Society for Clinical Oncology/ASCO Annual Meeting, updated interim data from the Phase 1b study for RLY-2608 were presented. In addition to oncology, Relay Therapeutics is continuing to execute its ongoing Phase 1 clinical trial for vascular malformations. Relay Therapeutics Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow?
Warren Buffett has struck again – this time in healthcare's rubble. Berkshire Hathaway (NYSE: BRK.B) recently disclosed a five million share position in United Healthcare Group (NYSE: UNH), the nation's largest health insurer. The timing is quintessentially Buffett. UNH shares have plummeted more than 50% from their all-time highs, battered by regulatory pressures and industry headwinds. While most investors flee the carnage, the Oracle of Omaha is doing what he does best – hunting for value in the wreckage. But as with everything Buffett does, context matters. Putting Things in Perspective The United Healthcare position is estimated to be worth around US$1.6 billion based on Berkshire's five million share purchase. That's a sizable sum of money by any measure. Here's what you need to know: Berkshire Hathaway's stock portfolio is worth close to US$295 billion. Therefore, the UNH position is less than 0.6% of the company's overall stock holdings. In contrast, Berkshire's largest position is actually Apple (NASDAQ: AAPL), valued at US$65 billion – representing more than a fifth of the total stock portfolio. Put simply, while the United Healthcare investment grabbed headlines, it wouldn't be moving Berkshire's needle anytime soon. Beyond that, there's a crucial question: did Buffett actually make this call? The Real Decision Makers Every Berkshire Hathaway stock purchase gets dissected as if it came straight from Warren Buffett himself. But the Oracle doesn't fly solo anymore. Berkshire brought on Todd Combs in 2010, followed by Ted Weschler in 2012. Both serve as investment managers with significant autonomy. Initially, Buffett allocated US$2 billion to each manager. By 2017, that figure had quintrupled to US$10 billion per person. Given this structure, the US$1.6 billion UNH bet could be from either Combs or Weschler – not Buffett himself. Get Smart: Look before you leap Context matters when it comes to investing. If you jump in and buy shares without understanding the full picture, you could get hurt in the process. For Berkshire, even if the UnitedHealth investment doesn't work out, you won't see the company sweating over a position worth less than 0.6%. Does the same apply to you? That's food for thought if you decide to pull the trigger. Dive into the future of technology with our newest FREE report, 'The Rise of Titans.' Discover how the big 7 US tech stocks can be your ticket to huge long-term gains. Download your copy today and see how easy it is to supercharge your portfolio. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Chin Hui Leong owns shares of Apple and Berkshire Hathaway The post Warren Buffett Buys a Beaten Down Healthcare Stock: Should You Follow? appeared first on The Smart Investor. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Blend Labs, Doma Technology Partner to Integrate AI for Faster, Cheaper Home Lending
Blend Labs Inc. (NYSE:BLND) is one of the most promising penny stocks under $5. Earlier on July 16, Blend Labs and Doma Technology announced an expanded partnership to integrate Doma's AI-powered instant title decisioning into Blend's home lending platform. This collaboration brings Doma's Upfront Title solution into Blend's flagship Mortgage & Rapid Home Lending solutions and is designed to help lenders close loans faster and save borrowers a significant amount of money on title costs. By embedding Upfront Title into the borrower application flow, the partnership creates a fully digital, end-to-end title and closing process. This allows lenders to obtain instant title decisions early in the process. The Upfront Title configuration also enables lenders to apply title insurance rates that can save borrowers between 40% and 70% compared to traditional rates. A close-up of a person's hand signing a mortgage document. This expansion aligns with Blend's strategic shift towards providing software-driven title solutions through partnerships rather than operating those services directly. This move follows Blend's recent definitive agreement to sell its title insurance business. Blend Labs Inc. (NYSE:BLND) provides a cloud-based software platform for financial services firms in the US. It operates in 2 segments: Blend Platform and Title. While we acknowledge the potential of BLND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
